This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

Urine dipstick demonstrates higher sensitivity and specificity than laboratory urinalysis for diagnosing urinary tract ...

Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

The global medical thawing system market was valued at $165.82 million in 2019 and is expected to reach $279.17 million by 2027 with a CAGR of 11.6% during the forecast period. Increase in incidences ...

This study presents a valuable open-source and cost-effective method for automating the quantification of male aggression and courtship in Drosophila melanogaster. The work as presented provides solid ...

Bottles of over-the-counter Benadryl sold on Amazon are being recalled nationwide because they pose a safety risk to children ...